KIG
KPTI icon

Kennedy Investment Group’s Karyopharm Therapeutics KPTI Stock Holding History

Kennedy Investment Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,333
Closed -$23.7K – 130
2024
Q4 		$23.7K Hold
2,333
– – 0.01% 123
2024
Q3 		$29.1K Hold
2,333
– – 0.01% 122
2024
Q2 		$30.4K Hold
2,333
– – 0.02% 118
2024
Q1 		$52.9K Hold
2,333
– – 0.03% 120
2023
Q4 		$30.3K Hold
2,333
– – 0.02% 121
2023
Q3 		$46.9K Hold
2,333
– – 0.03% 114
2023
Q2 		$62.6K Buy
2,333
+1,000
+75% +$43.1K 0.04% 114
2023
Q1 		$77.8K Buy
+1,333
New +$65.8K 0.05% 114

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Kennedy Investment Group's KPTI Position: Q1 2025 in Review

Kennedy Investment Group sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 2,333 shares — an estimated $23.7K sold.

Kennedy Investment Group first reported a position in KPTI in Q1 2023 and held it in 8 quarters. The position peaked at $77.8K in Q1 2023. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

  • Kennedy Investment Group reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Kennedy Investment Group sold 2,333 Karyopharm Therapeutics shares in Q1 2025, an estimated $23.7K.
  • Kennedy Investment Group first reported a position in Karyopharm Therapeutics in Q1 2023 and held it in 8 quarters.
  • Kennedy Investment Group's Karyopharm Therapeutics position peaked at $77.8K in Q1 2023.
  • 49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Kennedy Investment Group's 13F filing for Q1 2025, filed 22 Apr 2025.